HPC
CERE

HM Payson & Co’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

HM Payson & Co’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500
Closed -$20.4K – 1182
2024
Q2 		$20.4K Hold
500
– – ﹤0.01% 755
2024
Q1 		$21.1K Hold
500
– – ﹤0.01% 739
2023
Q4 		$21.2K Hold
500
– – ﹤0.01% 730
2023
Q3 		$10.9K Hold
500
– – ﹤0.01% 809
2023
Q2 		$15.9K Hold
500
– – ﹤0.01% 754
2023
Q1 		$12.2K Hold
500
– – ﹤0.01% 776
2022
Q4 		$15.8K Hold
500
– – ﹤0.01% 709
2022
Q3 		$14K Hold
500
– – ﹤0.01% 757
2022
Q2 		$13K Hold
500
– – ﹤0.01% 786
2022
Q1 		$18K Buy
+500
New +$14.6K ﹤0.01% 770

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HM Payson & Co's CERE Position: Q3 2024 in Review

HM Payson & Co sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 500 shares — an estimated $20.4K sold.

HM Payson & Co first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $21.2K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • HM Payson & Co reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • HM Payson & Co sold 500 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $20.4K.
  • HM Payson & Co first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • HM Payson & Co's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $21.2K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on HM Payson & Co's 13F filing for Q3 2024, filed 28 Oct 2024.